跳至主要内容
临床试验/ISRCTN45938399
ISRCTN45938399已完成3 期

A multicentre randomised trial of radical radiotherapy with carbogen in the radical radiotherapy of locally advanced bladder cancer

Cancer Research UK (CRUK) (UK)0 个研究点目标入组 0 人开始时间: 2001年7月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方

研究概览

简要总结

2009 Results article in https://www.ncbi.nlm.nih.gov/pubmed/18992952 early results 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33689854/ 10-year results (added 11/03/2021)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Aged 18 or over
  • 2. Histologically proven transitional cell carcinoma of the bladder
  • 3. Muscle invasive carcinoma (Stage T2 or T3) of any grade; G3 superficial bladder cancer (T1) or prostatic invasion T4a
  • 4. Ability to give informed consent
  • 5. Capable of complying with the use of a closed breathing system delivering carbogen through either a mask or a mouthpiece with nasal clip
  • 6. No squamous or adenocarcinoma of the bladder
  • 7. No locally advanced T4b carcinoma
  • 8. No presence of distant metastasis or enlarged lymph nodes on Computed Tomography (CT) staging scan of the pelvis
  • 9. No co-existing respiratory disease that contra-indicates delivery of 95% oxygen
  • 10. No impaired renal or hepatic function
  • 11. No ischeamic heart disease or peripheral vascular disease requiring treatment with diuretics or ACE inhibitors

排除标准

  • Not provided at time of registration

研究者

发起方
Cancer Research UK (CRUK) (UK)

相似试验